Aethlon medical announces financial results for the fiscal third quarter ended december 31, 2024 and provides corporate update

Key milestone achieved: first patient treated in hemopurifier® safety, feasibility, and dose finding study for solid tumors not responding to anti-pd-1 antibodies patient enrollment open at two australian for hemopurifier® cancer trial operating expenses significantly reduced conference call to be held today at 4:30 p.m. et san diego , feb. 12, 2025 /prnewswire/ -- aethlon medical, inc. (nasdaq: aemd), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended december 31, 2024 and provided an update on recent developments.
AEMD Ratings Summary
AEMD Quant Ranking